Current situation of oncology biosimilars in Japan

Lancet Oncol. 2021 Mar;22(3):e82. doi: 10.1016/S1470-2045(21)00029-2.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Biosimilar Pharmaceuticals* / adverse effects
  • Drug Approval
  • Humans
  • Japan
  • Medical Oncology
  • Policy

Substances

  • Biosimilar Pharmaceuticals